EMA completes review on colistin

EMA recommended updating and harmonising the Summary of Product Characteristics of nationally approved colistin products throughout the EU to reflect what is currently known. The recommendations focus mainly on optimising dosing schedules. Details here.

In spring 2013 an expert conference in Prato summarised the current knowledge on polymyxin drugs and laid the ground for awareness and the need to update the information: The Lancet Infectious Diseases

Categories: Uncategorized

Leave a Reply

Your email address will not be published. Required fields are marked *